A pharmaceutical company, dedicated to making ground-breaking, affordable medical solutions
accessible to everyone.
A pharmaceutical company, dedicated to making ground-breaking, affordable medical solutions
accessible to everyone.
Where pioneering science meets precision manufacturing. We are dedicated to advancing global healthcare by developing and delivering innovative pharmaceutical solutions. Explore our commitment to quality and our strategic approach to meet the needs of emerging markets.
Our pioneering development of SCEDAMIN, the first pediatric formulation of Hydroxyurea offers hope to those affected by sickle cell disease in emerging markets like Africa, while also making it accessible and cost-effective in the United States.
Make drugs affordable globally while ensuring their quality and accessibility in emerging markets."
Our diverse leadership team effectively navigates the global healthcare landscape, delivering innovative and affordable products, leveraging partnerships for global reach while adapting to new opportunities and risks.
Our Advisory Board, comprised of experts from academia, medicine, industry research and investment sectors, conducts thorough technological evaluations. The findings and recommendations of these evaluations inform strategic decisions.
We optimize drug delivery for pediatric formulations. Our custom formulations accelerate compound progress from discovery to manufacturing.
We provide pre-formulation testing, formulation comparisons, dosage form design, and optimization. We test multiple technical approaches in parallel, improving the probability of success and reducing time for critical formulation.
We improve the solubility and bioavailability of tough-to-formulate compounds. We create better versions of existing medications and offer customized product development programs.
We specialize in developing innovative and cost-effective pediatric, mini-tablet, and topical formulations in emerging markets worldwide through cross-functional teams.
We have invested in research and manufacturing to improve healthcare in emerging markets. Our expertise and compliance-focused infrastructure give us an edge, particularly in Africa.
We adhere to FDA, WHO, and cGMP guidelines in our state-of-the-art facilities, which undergo continuous improvement to fulfill international client requirements.
We have developed the first and only pediatric oral hydroxyurea formulation for sickle cell anemia patients in Africa. The body-weight adjusted dosing, dissolvable in water for oral administration within less than a minute.
Hydroxyurea is a prescription medication that reduces painful crises and the need for blood transfusions in children with sickle cell anemia aged 9 months and older. It may also lower the risk of complications, infections, and malaria.
Sickle cell anemia is associated with acute and chronic complications that lead to poor quality of life and early death. Hydroxyurea is an effective treatment, but few studies have been conducted in sub-Saharan Africa, where the burden is greatest.
WVU Innovation Corporation 781 Chestnut Ridge Road Morgantown, WV 26505
Open today | 09:00 am – 05:00 pm |
Monday - Friday: 9am - 5pm
Saturday - Sunday: Closed
Copyright © 2023 Yunigen Inc - All Rights Reserved.